ORIGINAL ARTICLE

Metaplastic breast carcinomas are negative for Her-2 but frequently express EGFR (Her-1): potential relevance to adjuvant treatment with EGFR tyrosine kinase inhibitors?

S Leibl, F Moinfar

J Clin Pathol 2005;58:700–704. doi: 10.1136/jcp.2004.025163

See end of article for authors' affiliations

Correspondence to:
Dr S Leibl, Department of
Pathology, Medical
University of Graz,
Auenbruggerplatz 25,
A-8036 Graz, Austria;
sebastian.leibl@
klinikum-graz.at

Accepted for publication
5 January 2005

Background: Metaplastic carcinomas (MCs) of the breast rarely express steroid receptors and Her-2, which minimises the options for adjuvant treatment in patients with advanced disease.

Aims: To investigate the possible eligibility of patients with MCs for epidermal growth factor receptor (EGFR) targeted treatment.

Methods: Immunohistochemical assessment of the expression of steroid receptors and four members of the EGFR/Her family (EGFR/Her-1–4) in 20 MCs (eight with heterologous elements, seven spindle cell MCs, four carcinosarcomas, and one matrix producing carcinoma). Fourteen of the 20 MCs were positive for EGFR (Her-1). Among these cases, 1+, 2+, and 3+ reactivity were seen in two, four, and eight cases, respectively. Her-2 was only present in one MC with 1+ reactivity. Her-3 (1+ reactivity), Her-4 (2+ reactivity), and the androgen receptor (2+ reactivity) were also expressed by one tumour. Oestrogen and progesterone receptors (3+ reactivity each) were detected in the epithelial component only of two carcinosarcoma-type MCs.

Conclusions: MCs express EGFR considerably more frequently than the types of breast carcinomas that have been investigated previously. Although molecular analyses for possible genetic alterations in the EGFR might be required, these results suggest that women suffering from this aggressive form of breast carcinoma might benefit from treatment with protein kinase inhibitors, such as gefitinib.

Because metaplastic carcinomas (MCs) of the breast rarely express steroid receptors,^{1–3} adjuvant endocrine treatment is usually not an option for these patients. Whereas adjuvant chemotherapy with Her-2 monoclonal antibodies (trastuzumab) is currently being tested in randomised clinical trials of patients suffering from metastatic breast carcinoma,^{4,5} treatment with monoclonal antibodies (Cetuximab, ABX-EGF, RH3, and MDX-447) against EGFR (Her-1) and small molecule inhibitors of EGFR—such as gefitinib (Iressa, ZD1839), Erlotinib, and EKB-569—is currently being tested in clinical trials of patients suffering from lung and colorectal cancer.⁶ The aim of our study was to evaluate the expression of steroid receptors and four members of the EGFR/Her family (EGFR/Her-1–4) in a collection of 20 MCs with no areas of squamous differentiation.

MATERIALS AND METHODS

Twenty MCs without areas of squamous differentiation (eight MCs with heterologous elements, seven spindle cell MCs, four carcinosarcomas, and one matrix producing carcinoma) were retrieved from the files of the department of pathology, Medical University of Graz, Austria. In each case, the haematoxylin and eosin diagnosis was verified by several basal cell-type cytokeratin and myoepithelial markers (such as CD10, smooth muscle actin, p63, maspin, and S100) in MCs with weak cytokeratin expression to rule out primary sarcoma of the breast.⁷ Formalin fixed, paraffin wax embedded tissue blocks were cut into 4 µm thick serial sections that were mounted on precoated slides. The sections were dewaxed, rehydrated, and rinsed in distilled water. Immunohistochemical assays for EGFR (Her-1), Her-2, Her-3, Her-4, and the androgen receptor were performed on consecutive paraffin wax sections using standardised automated procedures on a Dako Autostainer (DakoCytomation,

Glostrup, Denmark). For EGFR, the EGFR pharmDX kit (Dako), and for Her-2, the HercepTest (Dako), was used according to the manufacturer's instructions. In brief, sections were rinsed in phosphate buffered saline. Antigen retrieval for Her-2, Her-3, Her-4, and the androgen receptor was achieved by heating in a 1/10 dilution of epitope retrieval solution (Dako) at 98°C for 40 minutes, and for EGFR in a proteinase K solution (Dako) for five minutes. After cooling for 20 minutes, sections were rinsed in tap water and then loaded into the Dako autostainer (Dako), according to the computer generated reagent map. The Dako ChemMate detection kit was also used for antigen receptor visualisation.

Antigen retrieval for oestrogen and progesterone receptors was achieved by microwave heating in citrate buffer (pH 6.0) for 30 minutes at 160 W. For the following standardised procedures a Ventana (Illkirch, France) autostainer and a Ventana "iView" detection system were used.

Thereafter, all slides were gently rinsed with warm tap water, counterstained with haematoxylin, dehydrated, and mounted after xylol treatment with Entellan (Merck, Darmstadt, Germany). Table 1 summarises the antibodies and methods used.

Negative controls included substitution of the primary antibody with normal serum or phosphate buffered saline, omission of the secondary antibody, and incubation of the primary antibody solution with lymphoid tissue, respectively. For EGFR and Her-2 the control cell lines provided by the manufacturer (Dako) were also used in each run as negative and positive controls. Normal pancreatic or liver tissues were used as positive external controls for Her-3 and Her-4. In each case, the intensity of the immunostaining (negative, 1+, 2+, or 3+) and the percentage of tumour cells with positive

Abbreviations: EGFR, epidermal growth factor receptor; MC, metaplastic breast carcinoma; NSCLC, non-small cell lung cancer

Table 1 Summary of antibodies and methods used

Antigen	Test kit or antibody clone (manufacturer)	Dilution	Incubation time	Antigen retrieval
EGFR (Her-1)	EGFRpharmDX™ (Dako*)	Prediluted	30 minutes	Proteinase K solution for 5 minutes
Her-2	HercepTest™ (Dako*)	Prediluted	30 minutes	1/10 epitope retrieval solution (Dako) at 98°C for 40 minutes, then cooling in epitope retrieval solution for 20 minutes
Her-3, Ab-8	Clone SGP1 (Lab Vision†)	1/50	60 minutes	
Her-4, Ab-4	Clone HFR-1 (Lab Vision†)	1/50	30 minutes	
AR	Clone AR441 (Dako*)	1/50	30 minutes	
ER	Clone 6F11 (Ventana‡)	Prediluted	30 minutes	Citrate buffer (pH 6.0) in microwave (160 W) for 30 minutes
PR	Clone 1A6 (Ventana‡)	Prediluted	30 minutes	

*Glostrup, Denmark; †Freemont, California, USA; ‡Illkirch, France.
AR, androgen receptor; EGFR, epithelial growth factor receptor; ER, oestrogen receptor; PR, progesterone receptor.

staining were assessed according to the manufacturer's guidelines (Dako): 3+ membranous staining of more than 10% of tumour cells was required for Her-2 overexpression, and cytoplasmic only staining of EGFR was considered negative. All slides were evaluated independently by both authors. Those rare cases in which disagreement occurred were re-evaluated using a multiheaded microscope; a final agreement was reached in all cases.

RESULTS

Table 2 summarises the clinicopathological features of the 20 MCs. Histologically, three subtypes were evident, namely: (1) solid spindle cell proliferations with large areas of heterologous elements—that is, chondroid or osseous differentiation (nine cases including one matrix producing carcinoma; fig 1C and E); (2) pure spindle cell proliferations, which mostly exhibited interlacing spindle cell fascicles or trabeculae

Figure 1 (A) A metaplastic breast carcinoma (MC) with spindle cells arranged in an anastomosing trabecular pattern (haematoxylin and eosin staining; original magnification, $\times 400$), showing (B) 3+ epidermal growth factor receptor (EGFR) staining (original magnification, $\times 200$). (C) An MC with chondroid differentiation (haematoxylin and eosin staining; original magnification, $\times 400$) showing (D) 2+ EGFR staining (original magnification, $\times 400$). (E) An MC with osseous differentiation (haematoxylin and eosin staining; original magnification, $\times 400$) showing (F) 1+ EGFR staining; original magnification, $\times 400$. (G) An MC of the carcinosarcoma subtype showing a high grade invasive ductal carcinoma (arrow) set in a highly polymorphic sarcomatoid spindle cell background (haematoxylin and eosin staining; original magnification, $\times 400$). (H) Pan-cytokeratin staining highlighting the epithelial component of the carcinosarcoma shown in (G) (original magnification, $\times 400$). (I) Coexpression of EGFR in the sarcomatoid and in the epithelial component of the same case (original magnification, $\times 400$).

Table 2 Clinicopathological features of metaplastic breast carcinomas

Case/Histology	Age	T stage	N stage (n+/n)*
1 Spindle/het	64	pT3	pN1a /1/14)
2 Spindle/ep/het	91	pT1c	pN0
3 Spindle/ep/het/GC	37	pT2	pN1a (3/14)
4 Spindle/het/GC	62	pT2	pNx (0/1)
5 Spindle/het/GC	53	pT3	pN0 (0/12)†
6 Spindle/het/GC	41	pT2	pNx
7 Spindle/mat	60	pT1c	pN0 (0/9)
8 Spindle/het/GC	45	pT3	pN0 (0/37)‡
9 Spindle/het/apo	77	pT2	pN1a (3/12)
10 Spindle/fasc	75	pTx	pNx
11 Spindle/ep/GC	39	pT2	pN1a (1/18)
12 Spindle/fasc	73	pT2	pN0 (0/9)
13 Spindle/fasc	77	pT2	pN0 (0/10)
14 Spindle/fasc	74	pT4	pN0 (0/19)
15 Spindle/fasc	51	pT4a	pN0 (0/7)‡
16 Spindle/fasc	81	pT4c	pNx
17 Casa/spindle/GC	43	pT3	pN2a (5/12)
18 Casa/spindle	52	pT4c	pNx
19 Casa/spindle/fasc	44	pT1c	pN0 (0/9)
20 Casa/spindle/fasc	81	pT2	pNx

*n+/n, positive lymph nodes/total number of lymph nodes; †lung metastases 2 years after diagnosis of the primary tumour; ‡local recurrence 2 years after diagnosis of the primary tumour.
apo, apocrine features; casa, carcinosarcoma; ep, epithelioid; fasc, fascicular; GC, giant cells; het, heterologous elements; mat, matrix producing.

arranged in a whorled pattern, often concentrated around pre-existing ducts (seven cases; fig 1A); and (3) carcinosarcomas with a high grade invasive ductal carcinoma set in a sarcomatoid spindle cell or highly polymorphic background (four cases; fig 1G). Using the World Health Organisation criteria,² all cases (including the invasive ductal component of the carcinosarcomas) qualified as high grade tumours.

Immunohistochemically, 14 of the 20 MCs were positive for EGFR (table 3). Among these cases, 1+, 2+, and 3+

reactivity was seen in two, four, and eight cases, respectively. The percentage of tumour cells with 1+ EGFR immunoreactivity was 20%, and the percentage with 2+ and 3+ EGFR reactivity was 20–40% (mean, 25%) and 50–100% (mean, 76%), respectively.

Her-2 was only present in the spindle cells of one MC (1+ reactivity, not overexpressed) and in the epithelial component of two carcinosarcoma-type MCs (1+ and 2+ reactivity). Her-3 (1+ reactivity), Her-4 (2+ reactivity), and the androgen receptor (2+ reactivity) were positive in the spindle cells of one tumour and in the epithelial component of one carcinosarcoma-type MC (1+ and 2+ reactivity). Oestrogen and progesterone receptors (3+ reactivity each) were detected in the epithelial component only of two carcinosarcoma-type MCs. One carcinosarcoma-type MC (fig 1) showed coexpression of EGFR in the sarcomatoid and carcinomatous areas.

DISCUSSION

MCs comprise a very heterogeneous group of neoplasms, which show immunohistochemical evidence of myoepithelial differentiation ranging from “carcinomatous types”, with strong expression of basal cell type cytokeratins, to “sarcomatoid types”, with weak or absent cytokeratin expression.^{3–7,13} The five year survival rates of MCs vary considerably within the range of 28% to 68%,^{11–15} and some subtypes (especially carcinosarcomas) are very aggressive tumours that can present clinically as massive lesions.² Eight of our 20 MCs were large stage pT3 or pT4 tumours (table 2). Two patients suffered a local recurrence two years after surgery of the primary tumour, and one patient presented with lung metastases after the same disease free interval. In addition, nine of the 20 MCs occurred in younger women aged between 37 and 53. Because oestrogen and progesterone receptors and Her-2 overexpression are negative in most MCs,^{1–3,14} adjuvant endocrine treatment or Her-2 targeted treatment with a monoclonal antibody (trastuzumab) is usually not a therapeutic option in patients with advanced disease, positive resection margins, or positive lymph nodes.

Table 3 Expression of EGFR (Her-1), Her-2, Her-3, Her-4, and steroid receptors in metaplastic carcinomas

Case/Histology	Antigens (% of positive tumour cells/staining intensity)						
	EGFR	Her-2	Her-3	Her-4	AR	ER	PR
1 Spindle/het	20	2+	50/1+	–	–	–	–
2 Spindle/ep/het	70	3+	–	–	–	–	–
3 Spindle/ep/het/GC	40	2+	–	–	–	–	–
4 Spindle/het/GC	–	–	–	–	90/2+	–	–
5 Spindle/het/GC	20	1+	–	–	–	–	–
6 Spindle/het/GC	30	2+	–	–	–	–	–
7 Spindle/mat	10	2+	–	–	–	–	–
8 Spindle/het/GC	–	–	40/1+	40/2+	–	–	–
9 Spindle/het/apo	70	3+	–	–	–	–	–
10 Spindle/fasc	–	–	–	–	–	–	–
11 Spindle/ep/GC	–	–	–	–	–	–	–
12 Spindle/fasc	90	3+	–	–	–	–	–
13 Spindle/fasc	90	3+	–	–	–	–	–
14 Spindle/fasc	100	3+	–	–	–	–	–
15 Spindle/fasc	80	3+	–	–	–	–	–
16 Spindle/fasc	20	1+	–	–	–	–	–
17 Casa/IDC	–	–	30/2+	–	70/2+	70/3+	70/3+
17 Casa/spindle/GC	–	–	–	–	–	–	–
18 Casa/IDC	20	2+	–	–	–	–	–
18 Casa/spindle	50	3+	–	–	–	–	–
19 Casa/IDC	–	–	–	–	–	–	–
19 Casa/spindle/fasc	–	–	–	–	–	–	–
20 Casa/IDC	–	–	20/1+	20/1+	20/1+	30/3+	30/3+
20 Casa/spindle/fasc	60	3+	–	–	–	–	–

apo, apocrine features; AR, androgen receptor; casa, carcinosarcoma—epithelial staining; casa, carcinosarcoma—stromal staining; EGFR, epithelial growth factor receptor; ep, epithelioid; ER, oestrogen receptor; fasc, fascicular; GC, giant cells; het, heterologous elements; IDC, invasive ductal carcinoma; mat, matrix producing; PR, progesterone receptor.

EGFR (Her-1) is homologous to other members of the EGFR/erbB family, including Her-2 (erbB2), Her-3 (erbB3), and Her-4 (erbB4). Because aberrant signalling through the EGFR is associated with neoplastic cell proliferation, migration, stromal invasion, resistance to apoptosis, and angiogenesis,^{6, 16} it has emerged as an attractive target for anticancer treatments. Among the agents targeting EGFR (monoclonal antibodies such as cetuximab and small molecule inhibitors), the inhibitor furthest in development is gefitinib (ZD1839, Iressa). It was approved by the US Food and Drug Administration in 2003¹⁷ on the basis of two randomised phase 2 trials, which reported tumour responses in patients with non-small cell lung cancer (NSCLC) who had previously been treated with at least one platinum based regimen or who had received both platinum based and docetaxel chemotherapies.^{18, 19} Because two phase 3 trials showed no benefit for patients treated with gefitinib in combination with standard chemotherapy compared with standard chemotherapy alone,^{20, 21} gefitinib was only recommended for use as monotherapy. The EGFR protein is expressed by a variety of normal cells, including many epithelial cell types (such as squamous epithelium) and tumours derived from these cell types.²² In breast carcinomas, EGFR expression is associated with a poor prognosis,^{23–25} although its prognostic value seems to be dependent on the oestrogen receptor status of the patient also.^{23, 25, 26} More recent studies that used immunohistochemical staining for EGFR instead of ligand binding assays reported positivity for EGFR in 16.4%,²⁶ 20.1%,²⁷ and 26.9%²⁵ of breast carcinomas, which were mainly of the invasive ductal not otherwise specified type. In our study, EGFR was identified in 70% of MCs, whereas only one weakly expressed Her-2. Her-3, Her-4, and the androgen receptor were only detected in the spindle cells of one tumour, and progesterone/oestrogen receptors were negative in the spindle cells of all MCs. These results clearly show the difficult therapeutic situation in MCs compared with other high grade carcinomas of the breast, some of which at least have been shown to exhibit androgen receptors²⁸ and overexpress Her-2 as potential targets for adjuvant treatment. However, the frequent expression of EGFR in the absence of steroid receptors or other receptors of the EGFR family might render MCs even more sensitive to EGFR tyrosine kinase inhibitors, because it may reflect the crucial role of this receptor for tumour progression in most MCs, whereas endocrine and Her-2 dependent stimuli do not seem to contribute to tumour cell proliferation in these high grade tumours.

“The frequent expression of epidermal growth factor receptors (EGFRs) in the absence of steroid receptors or other receptors of the EGFR family might render metaplastic breast carcinomas even more sensitive to EGFR tyrosine kinase inhibitors”

Admittedly, the assessment of gefitinib sensitive NSCLS by immunohistochemistry has been seriously questioned by

recent studies reporting that specific mutations in certain EGFR exons, not simply kinase expression, render NSCLS sensitive to selective inhibitors.^{29–31} These results are consistent with positive responses to a protein kinase inhibitor (Imatinib) in patients suffering from gastrointestinal stromal tumours with kinase mutations.³² However, one has to remember that kinases in other tumour types might not necessarily have to be genetically altered to play a significant role in tumour cell proliferation and survival. An experimental study using breast cancer cell lines showed that EGFR overexpressing MDA-MB-231 cell lines and Her-2 overexpressing KPL-4 cell lines were more sensitive to gefitinib than other cell lines.³³ Because MCs express EGFR considerably more frequently than the types of breast carcinoma investigated immunohistochemically in previous studies,^{25–27} they represent a promising target for future studies (especially molecular analyses) on EGFR expression in breast carcinomas. Based on our results, patients suffering from this aggressive variant of breast carcinoma might benefit from treatment with protein kinase inhibitors such as gefitinib.

Authors' affiliations

S Leibl, F Moimfar, Department of Pathology, Medical University of Graz, Auenbruggerplatz 25, A-8036 Graz, Austria

REFERENCES

- 1 Bellino R, Arisio R, D'Addato F, *et al*. Metaplastic breast carcinoma: pathology and clinical outcome. *Anticancer Res* 2003;**23**:669–73.
- 2 Ellis IO, Schnitt SJ, Sastre-Garau X, *et al*. Invasive breast carcinoma. In: Tavassoli FA, Devilee P, eds. *WHO classification of tumours. Pathology and genetics of tumours of the breast and female genital organs*. Lyon: IARC Press, 2003:13–59.
- 3 Sneige N, Yaziji H, Mandavilli SR, *et al*. Low grade (fibromatosis-like) spindle cell carcinoma of the breast. *Am J Surg Pathol* 2001;**25**:1009–16.
- 4 Burris H 3rd, Yardley D, Jones S, *et al*. Phase II trial of trastuzumab followed by weekly paclitaxel/carboplatin as first-line treatment for patients with metastatic breast cancer. *J Clin Oncol* 2004;**22**:1621–9.
- 5 Vogel CL, Cobleigh MA, Tripathy D, *et al*. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. *J Clin Oncol* 2002;**20**:719–26.
- 6 Dancey JE, Freidlin B. Targeting epidermal growth factor receptor—are we missing the mark? *Lancet* 2003;**362**:62–4.
- 7 Leibl S, Gogg-Kammerer M, Sommersacher A, *et al*. Metaplastic breast carcinomas—are they of myoepithelial differentiation? Immunohistochemical profile of the sarcomatoid subtype using novel myoepithelial markers. *Am J Surg Pathol* 2005;**29**:347–53.
- 8 Dunne B, Lee AHS, Pinder SE, *et al*. An immunohistochemical study of metaplastic spindle cell carcinoma, phyllodes tumor and fibromatosis of the breast. *Hum Pathol* 2003;**34**:1009–15.
- 9 Popnikolov NK, Ayala AG, Graves K, *et al*. Benign myoepithelial tumors of the breast have immunophenotypic characteristics similar to metaplastic matrix-producing and spindle cell carcinomas. *Am J Clin Pathol* 2003;**120**:161–7.
- 10 Reis-Filho JS, Milanezi F, Paredes J, *et al*. Novel and classic myoepithelial/stem cell markers in metaplastic carcinomas of the breast. *Appl Immunohistochem Morphol* 2003;**11**:1–8.
- 11 Wargotz ES, Deos PH, Norris HJ. Metaplastic carcinomas of the breast. II. Spindle cell carcinoma. *Hum Pathol* 1989;**20**:732–40.
- 12 Wargotz ES, Norris HJ. Metaplastic carcinomas of the breast. I. Matrix-producing carcinoma. *Hum Pathol* 1989;**20**:628–35.
- 13 Wargotz ES, Norris HJ. Metaplastic carcinomas of the breast. III. Carcinosarcoma. *Cancer* 1989;**64**:1490–9.
- 14 Chieng C, Cranor M, Lesser ME, *et al*. Metaplastic carcinoma of the breast with osteocartilaginous heterologous elements. *Am J Surg Pathol* 1998;**22**:188–94.
- 15 Kaufman MW, Marti JR, Gallager HS, *et al*. Carcinoma of the breast with pseudosarcomatous metaplasia. *Cancer* 1984;**53**:1908–17.
- 16 Ellis LM, Hoff PM. Targeting the epidermal growth factor receptor: an important incremental step in the battle against colorectal cancer. *J Clin Oncol* 2004;**22**:1177–9.
- 17 Cohen MH, Williams GA, Sridhara R, *et al*. FDA drug approval summary: gefitinib (ZD1839) (Iressa) tablets. *Oncologist* 2003;**8**:303–6.
- 18 Fukuda M, Yano S, Giaccone G, *et al*. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer. *J Clin Oncol* 2003;**21**:2237–46.
- 19 Kris MG, Natale RB, Herbst RS, *et al*. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. *JAMA* 2003;**290**:2149–58.
- 20 Giaccone G, Herbst RS, Manegold C, *et al*. Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial—INTACT 1. *J Clin Oncol* 2004;**22**:777–84.

Take home messages

- Metaplastic breast carcinomas express the epidermal growth factor receptor more frequently than the types of breast carcinomas investigated previously
- Women suffering from this aggressive form of breast carcinoma might benefit from treatment with protein kinase inhibitors, such as gefitinib

- 21 **Herbst RS**, Giaccone G, Schiller JH, *et al*. Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial—INTACT 2. *J Clin Oncol* 2004;**22**:785–94.
- 22 **Gullick WJ**. Prevalence of aberrant expression of the epidermal growth factor receptor in human cancers. *Br Med Bull* 1991;**47**:87–98.
- 23 **Fox SB**, Smith K, Hollyer J, *et al*. The epidermal growth factor receptor as a prognostic marker: results of 370 patients and review of 3009 patients. *Breast Cancer Res Treat* 1994;**29**:41–9.
- 24 **Klijn JG**, Look MP, Portengen H, *et al*. The prognostic value of epidermal growth factor receptor (EGF-R) in primary breast cancer: results of a 10 year follow-up study. *Breast Cancer Res Treat* 1994;**29**:73–83.
- 25 **Tsutsui S**, Ohno S, Murakami S, *et al*. Prognostic value of epidermal growth factor receptor (EGFR) and its relationship to the estrogen receptor status in 1029 patients with breast cancer. *Breast Cancer Res Treat* 2002;**71**:67–75.
- 26 **Witton CJ**, Reeves JR, Going JJ, *et al*. Expression of the HER1–4 family of receptor tyrosine kinases in breast cancer. *J Pathol* 2003;**200**:290–7.
- 27 **Abd El-Rehim DM**, Pinder SE, Paish CE, *et al*. Expression and co-expression of the members of the epidermal growth factor receptor (EGFR) family in invasive breast carcinoma. *Br J Cancer* 2004;**91**:1532–42.
- 28 **Moinfar F**, Okcu M, Tsybrovskyy O, *et al*. Androgen receptors frequently are expressed in breast carcinomas: potential relevance to new therapeutic strategies. *Cancer* 2003;**98**:703–11.
- 29 **Lynch TJ**, Bell DW, Sordella R, *et al*. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. *N Engl J Med* 2004;**350**:2129–39.
- 30 **Paez JG**, Janne PA, Lee JC, *et al*. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. *Science* 2004;**304**:1497–500.
- 31 **Pao W**, Miller V, Zakowski M, *et al*. EGF receptor gene mutations are common in lung cancers from “never smokers” and are associated with sensitivity of tumors to gefitinib and erlotinib. *Proc Natl Acad Sci U S A* 2004;**101**:13306–11.
- 32 **Heinrich MC**, Corless CL, Demetri GD, *et al*. Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. *J Clin Oncol* 2003;**21**:4342–9.
- 33 **Okubo S**, Kurebayashi J, Otsuki T, *et al*. Additive antitumour effect of the epidermal growth factor receptor tyrosine kinase inhibitor gefitinib (Iressa, ZD1839) and the antiestrogen fulvestrant (Faslodex, ICI 182,780) in breast cancer cells. *Br J Cancer* 2004;**90**:236–44.

Clinical Evidence—Call for contributors

Clinical Evidence is a regularly updated evidence-based journal available worldwide both as a paper version and on the internet. *Clinical Evidence* needs to recruit a number of new contributors. Contributors are healthcare professionals or epidemiologists with experience in evidence-based medicine and the ability to write in a concise and structured way.

Areas for which we are currently seeking authors:

- Child health: nocturnal enuresis
- Eye disorders: bacterial conjunctivitis
- Male health: prostate cancer (metastatic)
- Women’s health: pre-menstrual syndrome; pyelonephritis in non-pregnant women

However, we are always looking for others, so do not let this list discourage you.

Being a contributor involves:

- Selecting from a validated, screened search (performed by in-house Information Specialists) epidemiologically sound studies for inclusion.
- Documenting your decisions about which studies to include on an inclusion and exclusion form, which we keep on file.
- Writing the text to a highly structured template (about 1500–3000 words), using evidence from the final studies chosen, within 8–10 weeks of receiving the literature search.
- Working with *Clinical Evidence* editors to ensure that the final text meets epidemiological and style standards.
- Updating the text every six months using any new, sound evidence that becomes available. The *Clinical Evidence* in-house team will conduct the searches for contributors; your task is simply to filter out high quality studies and incorporate them in the existing text.
- To expand the topic to include a new question about once every 12–18 months.

If you would like to become a contributor for *Clinical Evidence* or require more information about what this involves please send your contact details and a copy of your CV, clearly stating the clinical area you are interested in, to Klara Brunnhuber (kbrunnhuber@bmjgroup.com).

Call for peer reviewers

Clinical Evidence also needs to recruit a number of new peer reviewers specifically with an interest in the clinical areas stated above, and also others related to general practice. Peer reviewers are healthcare professionals or epidemiologists with experience in evidence-based medicine. As a peer reviewer you would be asked for your views on the clinical relevance, validity, and accessibility of specific topics within the journal, and their usefulness to the intended audience (international generalists and healthcare professionals, possibly with limited statistical knowledge). Topics are usually 1500–3000 words in length and we would ask you to review between 2–5 topics per year. The peer review process takes place throughout the year, and our turnaround time for each review is ideally 10–14 days.

If you are interested in becoming a peer reviewer for *Clinical Evidence*, please complete the peer review questionnaire at www.clinicalevidence.com or contact Klara Brunnhuber (kbrunnhuber@bmjgroup.com).